+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Partnerships, Licensing, Investments and M&A Deals and Trends for September 2019 in Pharmaceuticals

  • PDF Icon

    Report

  • 99 Pages
  • November 2019
  • Region: Global
  • GlobalData
  • ID: 4871363
Description Jump to:
Partnerships, Licensing, Investments and M&A Deals and Trends for September 2019 in Pharmaceuticals

Summary

Our “Partnerships, Licensing, Investments and M&A Deals and Trends for September 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry.

The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from Our proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Deal Values in Pharmaceutical and Healthcare Industry Has Increased in September 2019
1.1. Pharmaceuticals & Healthcare, Deals Summary, September 2019
2. Pharmaceuticals & Healthcare, Global, Deal Summary,
2.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2019
2.2. Pharmaceuticals & Healthcare, Global, Major Deals, September 2019
2.2.1. Thermo Fisher Scientific Raises USD5.7 Billion in Public Offering of Senior Notes
2.2.2. China Biologic Products Receives Non-Binding Acquisition Proposal from Buyer Group
2.2.3. Sumitomo Dainippon Pharma to Acquire 10% Stake in Roivant Sciences for USD3 Billion
2.2.4. Lundbeck to Acquire Alder BioPharma
2.2.5. Hansoh Pharma and Atomwise Enter into AI Drug Discovery Agreement
2.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, September 2019
2.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, September 2019
3. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type
3.1. Pharmaceuticals & Healthcare, Global, M&A, September 2019
3.1.1. Top M&A Deals in September 2019
3.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2019 - September 2019
3.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2019
3.2.1. Top Equity Offering Deals in September 2019
3.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, April 2019 - September 2019
3.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, September 2019
3.3.1. Top PE/VC Deals in September 2019
3.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, September 2019
3.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, September 2019
3.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, April 2019-September 2019
3.3.7. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2019-September 2019
3.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2019
3.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, April 2019 - September 2019
3.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), September 2019
3.6.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, September 2019
3.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
3.8. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, April 2019 - September 2019
3.9. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), April 2019 - September 2019
3.10. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
4. Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2019
4.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2019
4.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2019
4.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), April 2019 - September 2019
4.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), April 2019 - September 2019
4.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), April 2019 - September 2019
4.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), April 2019 - September 2019
4.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, September 2019
4.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2019
4.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2019
5. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
5.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, September 2019
5.1.1. Oncology - Deals of the Month
5.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, September 2019
5.2.1. Central Nervous System - Deals of the Month
5.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, September 2019
5.3.1. Infectious Diseases - Deals of the Month
5.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, September 2019
5.4.1. Cardiovascular - Deals of the Month
5.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, September 2019
5.5.1. Immunology - Deal of the Month
5.6. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, September 2019
5.6.1. Gastrointestinal - Deals of the Month
5.7. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, September 2019
5.7.1. Metabolic Disorders - Deals of the Month
6. Deal Summary by Geography
6.1. Pharmaceuticals & Healthcare, North America Deals, September 2019
6.1.1. North America - Deals of the Month
6.2. Pharmaceuticals & Healthcare, Europe, Deals, September 2019
6.2.1. Europe - Deals of the Month
6.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, September 2019
6.3.1. Asia-Pacific - Deals of the Month
6.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, September 2019
6.4.1. Rest of the World - Deals of the Month
7. Pharmaceuticals & Healthcare, Global, Top Financial Advisors
7.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, April 2019 - September 2019
7.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, April 2019 - September 2019
8. Further Information
8.1. Methodology
8.2. About the Author
8.3. Contact Us
8.4. Disclosure information
8.5. Disclaimer
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, September 2019
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), September 2019
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, September 2019
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2019 - September 2019
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, September 2019
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, September 2019
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, April 2019 - September 2019
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), September 2019
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2019 - September 2019
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), September 2019
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2019 - September 2019
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), April 2019 - September 2019
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), September 2019
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2019 - September 2019
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2019
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, September 2019
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, September 2019
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, September 2019
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
List of Figures
Figure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, September 2019
Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, April 2019 - September 2019
Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, September 2019
Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, September 2019
Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), September 2019
Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), September 2019
Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2019 - September 2019
Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2019 - September 2019
Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), September 2019
Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), September 2019
Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2019 - September 2019
Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2019 - September 2019
Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2019 - September 2019
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, April 2019 - September 2019
Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), April 2019 - September 2019
Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), September 2019
Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 36: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2019 - September 2019
Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2019 - September 2019

Related Topics

Related Reports

Licensing Deals in Pharmaceuticals 2019-2024 - Product Image

Licensing Deals in Pharmaceuticals 2019-2024

  • Report
  • 1300 Pages
  • Global
From
Collaboration Deals in Pharmaceuticals 2019-2024 - Product Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • 1000 Pages
  • Global
From
Drugs for Erectile Dysfunction Global Market Report 2024 - Product Image

Drugs for Erectile Dysfunction Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Oligonucleotide Therapy Global Market Report 2024 - Product Image

Oligonucleotide Therapy Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Thin Film Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028) - Product Image

Thin Film Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

  • Report
  • 110 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.